title: FDG PET/CT in evaluation of unusual cutaneous manifestations of breast cancer.
abstract: Cutaneous metastases of primary internal malignancies are rare, with an incidence of 0.7% to 10.4%. Cutaneous manifestations due to breast cancer are the most common metastases dermatologists observe, with a prevalence of 2.4% and an incidence of 23.9%. Presence of cutaneous metastases is usually a late event in disease progression, indicating grave prognosis. Recognition of cutaneous breast cancer metastases significantly alters therapeutic plans, especially when the disease was thought to be successfully cured. F-FDG PET CT imaging can detect cutaneous metastasis and sites of distant metastases and monitor response to therapy. We report 3 patients with cutaneous-predominant breast carcinoma seen by FDG PET/CT.
authors.affiliation: From the *Department of Medicine, †Hematology/Oncology Section, ‡Nuclear Medicine Section, Department of Radiology, and §Anatomic Pathology Section, Department of Pathology, Medical College of Georgia at Georgia Regents University, Augusta, GA.
authors.forename: Shaylee R
authors.initials: SR
authors.lastname: Dave
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Samuel
authors.forename: Darko
authors.initials: D
authors.lastname: Pucar
authors.forename: Natasha
authors.initials: N
authors.lastname: Savage
authors.forename: Hadyn T
authors.initials: HT
authors.lastname: Williams
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000473:pathology; D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012878:Skin Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18